Capitalization 103M 67.58M 5.24B P/E ratio 2024 *
-
P/E ratio 2025 * 13.9x
Enterprise value 276M 182M 14.08B EV / Sales 2024 *
0.64x
EV / Sales 2025 * 0.72x
Free-Float
0%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+4.17%
1 week-3.85%
Current month+25.00%
1 month+13.64%
3 months-19.35%
6 months-34.21%
Current year-37.50%
More quotes
1 week
0.12
Extreme 0.12
0.13
1 month
0.10
Extreme 0.1
0.14
Current year
0.10
Extreme 0.097
0.26
1 year
0.10
Extreme 0.097
0.47
3 years
0.10
Extreme 0.097
1.53
5 years
0.10
Extreme 0.097
1.60
10 years
0.10
Extreme 0.097
1.60
More quotes
Insider TitleAgeSince
Founder - 31/12/10
President - 31/12/11
Chief Operating Officer - 31/10/14
Insider TitleAgeSince
Chairman - 27/09/16
Founder - 31/12/10
Director/Board Member - 27/09/16
More insiders

Financials

Ratios2024 *2025 *
Net sales 124M 81.28M 6.3B 120M 78.86M 6.11B
Net income -9.9M -6.51M -505M 5.7M 3.75M 291M
Net Debt -23.4M -15.4M -1.19B -15.95M -10.5M -814M
More financial data * Estimated data
Logo BIGN HLDG
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
Employees
495
Sector
-
More about the company
Date Price Change Volume
24/07/24 0.1250 $ +4.17% 229 121
23/07/24 0.1200 $ 0.00% 6,245,750
22/07/24 0.1200 $ 0.00% 302,743
19/07/24 0.1200 $ 0.00% 208,243
18/07/24 0.1200 $ -4.00% 735,354

Delayed Quote Australian S.E., July 24, 2024 at 07:10 am

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.1250AUD
Average target price
0.2500AUD
Spread / Average Target
+100.00%
Consensus

Annual profits - Rate of surprise